Skip to content

13F-HR filed by Opaleye Management Inc.

Opaleye Management Inc. filed this 13F-HR for the quarter ended 2018-06-30, filed 2018-08-14, with 36 holding rows worth $386,358,000.

Accession
0001493152-18-011830
Filed
2018-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2018

A holdings report, 36 entries on the cover page, a total value of $386,358,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $386,358,000 with VALUE read as thousands by filing date, 13F file number 028-15896. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
AXOGEN INC05463X106COM1,440,000$72,360,000thousands by filing date
LOXO ONCOLOGY INC548862101COM175,000$30,359,000thousands by filing date
CODEXIS INC192005106COM1,750,000$25,200,000thousands by filing date
FIBROGEN INC31572Q808COM360,000$22,536,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM350,000$22,218,000thousands by filing date
POLARITYTE INC731094108COM800,000$18,832,000thousands by filing date
DECIPHERA PHARMACEUTICALS IN24344T101COM420,000$16,527,000thousands by filing date
VIKING THERAPEUTICS INC92686J106COM1,200,000$11,388,000thousands by filing date
STRONGBRIDGE BIOPHARMA PLCG85347105SHS USD1,830,000$10,980,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM130,000$10,949,000thousands by filing date
FENNEC PHARMACEUTICALS INC31447P100COMMON STOCK945,000$9,865,000thousands by filing date
CYMABAY THERAPEUTICS INC23257D103COM697,500$9,360,000thousands by filing date
TG THERAPEUTICS INC COM88322Q108Stock625,000$8,218,000thousands by filing date
AMAG PHARMACEUTICALS INC00163U106COM420,000$8,190,000thousands by filing date
MIRAGEN THERAPEUTICS INC60463E103COM1,200,000$7,692,000thousands by filing date
OCULAR THERAPEUTIX INC67576A100COM1,111,000$7,499,000thousands by filing date
DIANTHUS THERAPEUTICS INC COM55910K108Stock550,000$7,425,000thousands by filing date
AUDENTES THERAPEUTICS INC.05070R104Common Stock190,000$7,259,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM505,000$7,171,000thousands by filing date
XOMA ROYALTY CORPORATION98419J206COMMON STOCK320,200$6,685,000thousands by filing date
XENCOR INC98401F105COMMON STOCK180,000$6,661,000thousands by filing date
CORIUM INTL INC21887L107COM800,000$6,408,000thousands by filing date
CIDARA THERAPEUTICS INC COM NEW171757107Stock1,200,000$6,240,000thousands by filing date
ULTRAGENYX PHARMACEUTICAL IN90400D108COM80,000$6,149,000thousands by filing date
PTC THERAPEUTICS INC69366J200COM180,000$6,071,000thousands by filing date
APELLIS PHARMACEUTICALS INC03753U106COM265,000$5,830,000thousands by filing date
CHIMERIX INC COM16934W106Stock1,150,000$5,474,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW1,750,000$5,407,000thousands by filing date
BIOFRONTERA AG ADR09075G105COM391,400$4,755,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS250,000$3,827,000thousands by filing date
EPIZYME INC29428V104COM275,000$3,726,000thousands by filing date
ARQULE INC04269E107COM420,000$2,322,000thousands by filing date
PROTALIX BIOTHERAPEUTICS INC74365A101COM3,100,000$1,333,000thousands by filing date
CTI BIOPHARMA CORP12648L601COM161,400$803,000thousands by filing date
AZURRX BIOPHARMA INC05502L105COM130,000$417,000thousands by filing date
BIOLINERX LTD-SPONS ADR09071M106SPON250,000$222,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001493152-18-011830this filing2018-08-14acceptance time not in the bulk data set